Permanent Iodine 125 implant brachytherapy in localized prostate cancer: Results of the first 4 years of experience;La curiethérapie par implants permanents d'iode 125 dans le cancer localisé de prostate: Résultats des 4 premières années d'expérience

Progres en Urologie

Volumn 14, Issue 3, 2004, Pages 345-352

  Bladou, Franck ^a   Salem, Naji ^a   Simonian Sauve, Michelle ^a   Rosello, Roland ^a   Ternier, Frédéric ^a   Resbeut, Michel ^a   Alzieu, Claude ^a   Karsenty, Gilles ^a   Serment, Gérard ^a   Gravis, Gwenaëlle ^b   Maraninchi, Dominique ^b  

^a Child and Adolescent Psychopathology Unit Salvator Hospital Public Assistance Marseille Hospitals University Aix Marseille II   (France)

^b INSTITUT PAOLI CALMETTES   (France)

Author keywords

Brachytherapy; Prostate cancer; Radiotherapy; Ultrasound

Indexed keywords

IODINE 125;

ARTICLE; CANCER CONTROL; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DATA ANALYSIS; DOSIMETRY; ENDOSCOPIC THERAPY; ERECTILE DYSFUNCTION; HIGH RISK PATIENT; HUMAN; IMPLANT; INTERSTITIAL RADIATION; MAJOR CLINICAL STUDY; MALE; MICTURITION; PATIENT SELECTION; PROCTITIS; PROSTATE CARCINOMA; RADIATION DEPTH DOSE; RADIATION DOSE; RADIATION INJURY; SCORING SYSTEM; URINE RETENTION;

ADENOCARCINOMA; AGED; BRACHYTHERAPY; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; TIME FACTORS;

EID: 4143087090     PISSN: 11667087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. SMART C.R. : The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program. Cancer 1997 ; 80 : 1835-1844.
2. REBILLARD X., VILLERS A. : Cancer de la prostate. Progrès en urologie, 2002 ; 12 : 29-67.
3. LU-YAO G.L., GREENBERG E.R. : Changes in prostate cancer incidence and treatment in USA. Lancet, 1994 ; 343 : 251-254.
4. ALDOFSSON J., RONSTROM L., LOWHAGEN T., CARSTENSEN J., HEDLUND P.O. : Deferred Treatment of clinically localized low grade prostate cancer: the experience from a prospective series at the Karolinska Hospital. Journal of Urology, 1994 ; 152 : 1757-1760.
5. LU-YAO G.L., YAO S.L. : Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet, 1997 ; 349 : 906-910.
6. POLLACK A., ZAGARS G.K. : External beam radiotherapy for stage T1/T2 prostate cancer: How does it stack up? Urology, 1998 ; 51 : 258-264.
7. MIDDLETON R.G., THOMPSON I.M., AUSTENFELD M.S., COONER W.H., CORREA R.J., GIBBONS R.P. : Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. J. Urol., 1995 ; 154 : 2144-2148.
8. RAGDE H., ELGAMAL A.A., SNOW P.B., BRANDT J., BARTOLUCCI A.A., NADIR B.S. : Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer, 1998 ; 83 : 989-1001.
9. BLASKO J.C., RAGDE H., GRIMM P.D. : Transperineal ultrasound-guided implantation of the prostate: Morbidity and complications. Scand. J. Urol. Nephrol. Suppl., 1991 ; 137 : 113-118.
10. STOCK R.G., STONE N.N., IANNUZZI C. : Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1996 ; 35 : 267-272.
11. BLASKO J.C., RAGDE H., GRIMM P.D., CAVANAGH W. : Prostate brachytherapy: Importance of technique. J. Clin. Oncol., 1996 ; 14 : 1965-1967.
12. WALLNER K., ROY J., HARRISON L. : Dosimetry guidelines to minimize urethral and rectal morbidity following transperineal I-125 prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys., 1995 ; 32 : 465-471.
13. SIMONIAN-SAUVE M., SMART C., MAILLEUX H., ROSELLO R., BLADOU F., SALEM N. : Curiethérapie prostatique transpérinéale par Iode-125 avec dosimétrie prévisionnelle: analyse des résultats dosimétriques pré- et post-implantation. Cancer Radiother., 2003 ; 7 : 90-99.
14. NAG S., BICE W., DEWYNGAERT K., PRESTIDGE B., STOCK R., YU Y. : The American Brachytherapy Society recommendations for permanent prostate brachytherapy postimplant dosimetric analysis. Int. J. Radiat. Oncol. Biol. Phys., 2000 ; 46 : 221-230.
15. WALLNER K., LEE H., WASSERMAN S., DATTOLI M. : Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resection. Int. J. Radiat. Oncol. Biol. Phys., 1997 ; 37 : 565-569.
16. STOCK R.G., STONE N.N., TABERT A., IANNUZZI C., DEWYNGAERT J.K. : A dose-response study for I-125 prostate implants. Int. J. Radiat. Oncol. Biol. Phys., 1998 ; 41 : 101-108.
17. MERRICK G.S., BUTLER W.M., WALLNER K.E., GALBREATH R.W., ANDERSON R.L. : Prostate-specific antigen spikes after permanent prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys., 2002 ; 54 : 450-456.
18. WALLNER K., ROY J., ZELEFSKY M., FUKS Z., HARRISON L.. : Short-term freedom from disease progression after iodine-125 prostate implantation. Int. J. Radiat. Oncol. Biol. Phys., 1994 ; 30 : 405.
19. STOREY M.R., LANGREN R.C., COTTONE J.L., STALLINGS J.W., LOGAN C.W., FRAISER L.P., ROSS C.S. : Transperineal I-125 implantation for treatment of clinically localized prostate cancer. 5-year tumor control and morbidity. Int. J. Radiat. Oncol. Biol. Phys., 1999 ; 43 : 565-570.
20. BEYER D.C., PRIESTLEY J.B. : Biochemical disease-free following 125 I implantation. Int. J. Radiat. Oncol. Biol. Phys., 1987 ; 37 : 559-553.
21. ZELEFSKY M.J., HOLLISTER T., RABEN A., MATTHEWS S., WALLNER K.E. : Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 2000 ; 47 : 1261-1266.
22. KAYE K.W., OLSON D.J., PAYNE J.T. : Detailed preliminary analysis of iodine-125 implantation for localized prostate cancer using percutaneous approach. J. Urol., 1995 ; 153 : 1020-1025.
23. DATTOLI M.J., WALLNER K., SORACE R., KOVAL J., CASH J., ACOSTA R., EBROWN C., ETHERIDGE J., BINDER M., B RUNELLE R., KIRWEN N., SANCHEZ S., STEIN D., WASSERMAN S. : 103Pd brachytherapy and external beam irradiation for clinically localized; high-risk prostatic carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 1996 ; 35 : 875-879.
24. TERK M.D., STOCK R.G., STONE N.N. : Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J. Urol., 1998 ; 160 : 1379-1382.
25. LEE N., WUU C.S., BRODY R., LAGUNA J.L., KATZ A.E., BAGIELLA E. ENNIS R.D. : Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys., 2000 ; 48 : 1457-1460.
26. BENOIT R.M. NASLUND M.J., COHEN J.K. Complications after prostate brachytherapy in the Medicare population. Urology, 2000 ; 55 : 91-96.
27. DESAI J., STOCK R.G., STONE N.N., IANNUZZI C., DEWYNGAERT J.K. : Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. Radiat. Oncol. Investig., 1998 ; 6 : 135-141
28. GELBLUM D.Y., POTTERS L., ASHLEY R., WALDBAUM R., WANG X.H., LEIBEL S. : Urinary morbidity following ultrasoud-guided transperineal prostate seed implantation. Int. J. Radiat. Oncol. Biol. Phys., 1999 ; 45: 59-67
29. BROWN D., COLONIAS A., MILLER R., BENOIT R., COHEN J., ARSHOUN Y., GALLOWAY M., KARLOVITS S., WU A., JOHNSON M., QUINN A., KALNICKI S. : Urinary morbidity with a modified periferal loading technique of transperineal 125-I prostate implantation. Int. J. Radiat. Oncol. Biol. Phys., 2000 ; 47 : 353-360.
30. SALEM N., SIMONIAN-SAUVE M., ROSELLO R., ALZIEU C., GRAVIS G., MARANINCHI D., BLADOU F. : Predictive factors of acute urinary morbidity after iodine-125 brachytherapy for localized prostate cancer: a phase 2 study. Radiother. Oncol., 2003 ; 66 : 159-165.
31. KRUMHOLTZ J.S., MICHALSKI J.M., SUNDARAM C.P. : Health-related quality of life and morbidity in patients receiving brachytherapy for clinically localized prostate cancer. J. Endourol., 2000 ; 14 : 371-374.
32. GELBLUM D.Y., POTTERS L. : Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 2000 ; 48 : 119-124.
33. KLEINBERG L., WALLNER K., ROY J., ZELEFSKY M., ARTERBERY V.E., FUKS Z., HARRISON L. : Treatment-related symptoms during the first year following transperineal 125-I prostate implantation. Int. J. Radiat. Oncol. Biol. Phys., 1994 ; 28 : 985-990.
34. MERRICK G.S., BUTLER W.M., DORSEY A.T., GALBREATH R.W., BLATT H., LIEF J.H. : Rectal function following prostate brachytherapy. Int. J. Radiat. Oncol. Biol. Phys., 2000 ; 48 : 667-674.
35. STOCK R.G., STONE N.N., IANNUZZI C. : Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1996 ; 35 : 267-272.
36. SANCHEZ-ORTIZ R.F., BRODERICK G.A., ROVNER E.S., WEIN A.J., WHITTINGTON R., MALKOWICZ S.B. : Erectile function and quality of life after interstitial radiation therapy for prostate cancer. Int. J. Impotence Res., 2000 ; 12 : 18-24.
37. MERRICK G.S., BUTLER W.M., DORSEY A.T., LIEF J.H., DONZELLA J.G. : A comparison of radiation dose to the neurovascular bundles in men with and without prostate brachytherapy-induced erectile dysfunction. Int. J. Radiat. Oncol. Biol. Phys., 2000 ; 48 : 1069-1074.
38. INCROCCI L., KOOS SLOB A., LEVENDAG P.C. : Sexual (dysfunction after radiotherapy for prostate cancer: a review. Int. J. Radiat. Oncol. Biol. Phys., 2002 ; 52 : 681-693.
39. MERRICK G.S., BUTLER W.M., LIEF J.H., STIPETICH R.L., ABEL L.J., DORSEY A.T. : Efficacy of sildenafil citrate in prostate brachytherapy patients with erectile dys-function. Urology, 1999 ; 53 : 1112-1116.
40. NAG S., BEYER D., FRIEDLAND J., GRIMM P., NATH R. : American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 1999 ; 44 : 789-799.
41. LEE R.L., DEGUZMAN A.F., BARE R.L., MARSHALL M.G., McCULLOUGH D.L. : Postimplant analysis of transperineal interstitial permanent prostate brachytherapy: evidence for a learning curve in the first year at a single institution. Int. J. Radiat. Oncol. Biol. Phys., 2000 ; 46 : 83-88.
42. BLASKO J.C., GRIMM P., SYLVESTER J., BADIOZAMANI K.R., HOAK D., CAVANAGH W. : Palladium-103 brachytherapy for prostate carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 2000 ; 46 : 839-850.
43. RAGDE H., LEROY J.K., ELGAMAL A.A., GRADO G., NADIR B.S. : Modern Prostate Brachytherapy Prostate Specific Antigen Results in 219 Patients with up to 12 Years of Observed Follow-Up. Cancer, 2000 ; 89 : 135-141.
44. STOREY M.R., LANDGREN R.C., COTTONE J.L., STALLINGS J.W., LOGAN C.W., FRAISER L.P. : Transperineal I-125 implantation for treatment of clinically localized prostate cancer. 5-year tumor control and morbidity. Int. J. Radiat. Oncol. Biol. Phys., 1999 ; 43 : 565-570.
45. ZELEFSKY M.J., HOLLISTER T., RABEN A., MATTHEWS S., WALLNER K.E. : Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys., 2000 ; 47 : 1261-1266.